From: Mayo Clin Proc. Oct 2012; 87(10): 935-943.

doi: 10.1016/j.mayocp.2012.07.007

Copyright/License ► Request permission to reuse

TABLE

Cost of Selected Drugs Used in Cancer Therapy^a

MAYO CLINIC

Generic drug name (trade name; manufacturer, location)	Cancer	Typical treatment schedule	Cumulative drug cost for 1 y (\$)	Comments
Ipilimumab (Yervoy; Bristol-Myers Squibb, New York, NY)	Melanoma	Once every 3 wk for 4 doses	120,000	Duration not well defined; currently, physicians have been going past the 4 doses if patients have achieved a good response
Sipuleucel-T (Provenge; Dendreon Corp, Seattle, WA)	Prostate cancer	Three doses over 1 mo	90,000 for 3 doses	
Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA)	Various cancers, including lung and colon cancer	Once every 3- 4 wk	90,000	Can be continued >1 y until disease progression
Paclitaxel, protein-bound (Abraxane; Celgene Corp, Summit, NJ)	Breast cancer	Three times a month	80,000	Continued until disease progression
Lenalidomide (Revlimid; Celgene Corp)	Multiple myeloma	Daily for 3 wk of each	90,000	In frontline and maintenance, duration of therapy can exceed 3 y; in relapsed disease, duration is

	month	approximately 1 y
Bortezomib (Velcade; Millennium Multiple my Pharmaceuticals, Cambridge, MA)	reloma Once weekly 60,000	Can be continued >1 y until disease progression
Imatinib mesylate (Gleevec; Chronic my Novartis Pharmaceuticals Corp, leukemia East Hanover, NJ)	eloid Once daily 70,000	Lifelong until progression
Alemtuzumab (Campath; Genzyme Chronic leu Corp, Cambridge, MA)	kemias Three times a 70,000 week for 3 mo	Could be used for >1 y
Ofatumumab (Arzerra; Lymphoma: GlaxoSmithKline, Philadelphia, chronic lymphoma: PA) leukemias		Could be used for >1 y
Brentuximab vedotin (Adcetris; Hodgkin lyn Seattle Genetics Inc, Bothell, WA)	mphoma Once every 21 100,000 d for 8 cycles	Approximately 6-8 cycles in a year
Dasatinib (Sprycel; Bristol-Myers Chronic my Squibb) leukemia	eloid Once daily 110,000	Lifelong until progression

^aThe costs listed are approximate estimates based on average wholesale prices and typical schedules used in practice. Costs are higher when the cost of administration is factored in and when 2 or more drugs are used in combination.